{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-041883","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2026-06-09T20:05:26+00:00","discovered_at":"2026-06-09T20:07:00.365463+00:00","generated_at":"2026-06-09T20:08:58.043346+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Shareholders approve all proposals; board adopts updated director compensation program","bullets":["Three Class III directors elected: Patrick J. Heron, Neha Krishnamohan, Todd Franklin Watanabe.","Ernst & Young ratified as independent auditor for fiscal year 2026.","Non-binding advisory vote approved named executive officer compensation.","Revised director comp: $50k base retainer, $350k initial option, annual $350k award (65% options, 35% RSUs)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-041883","json":"https://secwatch.observer/filing/0001628280-26-041883.json","markdown":"https://secwatch.observer/filing/0001628280-26-041883.md","text":"https://secwatch.observer/filing/0001628280-26-041883.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/0001628280-26-041883-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/arqt-20260605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T20:08:58.043346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51ed2065cc1a387fda13c25f1c27ea884e5f3445","claim":"Arcutis Biotherapeutics, Inc. shareholders approved Non-binding advisory approval of the compensation of the Company's named executive officers at the 2026-06-05 meeting.","evidence_excerpt":"Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/0001628280-26-041883-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-05"}],"fact_type":"shareholder_vote"},{"claim_id":"958e2520e9154816247d3be7f20a8ff834abfdea","claim":"Arcutis Biotherapeutics, Inc. shareholders approved Election of three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected at the 2026-06-05 meeting.","evidence_excerpt":"Proposal 1. The election of three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/0001628280-26-041883-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-05"}],"fact_type":"shareholder_vote"},{"claim_id":"d849f0d7d8a34ea519e4ef2b1fa8faed8c71e474","claim":"Arcutis Biotherapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-05 meeting.","evidence_excerpt":"Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/0001628280-26-041883-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-05"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}